Donald Fell was appointed as Director at Tevogen Bio Holdings Inc..
“Michael Peterson, Donald Fell, Avinaesh Wadhwani, Scott Sussman, and Surendra Ajjarapu were appointed as members of the Board”
Tevogen Bio Holdings Inc. — fact timeline
Source-grounded facts extracted from Tevogen Bio Holdings Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Michael Peterson was appointed as Director at Tevogen Bio Holdings Inc..
“Michael Peterson, Donald Fell, Avinaesh Wadhwani, Scott Sussman, and Surendra Ajjarapu were appointed as members of the Board”
Jeff Rogers resigned as Officer at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Ben Baldanza, and Jeff Rogers resigned as officers of the Company”
Ben Baldanza resigned as Officer at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Ben Baldanza, and Jeff Rogers resigned as officers of the Company”
Hooman Yazhari resigned as Officer at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Ben Baldanza, and Jeff Rogers resigned as officers of the Company”
Richard N. Peretz resigned as Officer at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Ben Baldanza, and Jeff Rogers resigned as officers of the Company”
Parizad Olver Parchi resigned as Director at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Paul P. Jebely, Brad Stewart, and Parizad Olver Parchi (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company”
Brad Stewart resigned as Director at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Paul P. Jebely, Brad Stewart, and Parizad Olver Parchi (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company”
Paul P. Jebely resigned as Director at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Paul P. Jebely, Brad Stewart, and Parizad Olver Parchi (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company”
Hooman Yazhari resigned as Director at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Paul P. Jebely, Brad Stewart, and Parizad Olver Parchi (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company”
Richard N. Peretz resigned as Director at Tevogen Bio Holdings Inc..
“Richard N. Peretz, Hooman Yazhari, Paul P. Jebely, Brad Stewart, and Parizad Olver Parchi (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company”
Tevogen Bio Holdings Inc. entered into Purchase Agreement with SSVK Associates, LLC and Semper Paratus Sponsor LLC valued at $1.00 (effective 2023-05-04).
“On May 4, 2023, the Company entered into a purchase agreement (the “Purchase Agreement”) with SSVK Associates, LLC (the “Acquirer”) and the Sponsor, pursuant to which the Acquirer will purchase from the Sponsor (x) 7,988,889 Class A Ordinary Shares and (y) 1,000,000 private placement units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant that is exercisable for one Class A Ordinary Share, free and clear of all liens and encumbrances (other than those contained in the Letter Agreement, dated November 3, 2021, by and among the Company, its officers, directors and the Sponsor, and the Underwriting Agreement, dated November 3, 2021, by and between the Company and Cantor Fitzgerald & Co., as representative of the several underwriters (the “Underwriting Agreement”)), for an aggregate purchase price of $1.00 (the “Purchase Price”) payable at the time of the initial business combination.”
Tevogen Bio Holdings Inc. entered into Subscription Agreement with Polar Multi-Strategy Master Fund and Semper Paratus Sponsor LLC valued at $151,000 (effective 2023-05-03).
“On May 3, 2023, Semper Paratus Acquisition Corporation (the “Company”) entered into a subscription agreement (“Subscription Agreement”) with Polar Multi-Strategy Master Fund (the “Investor”) and Semper Paratus Sponsor LLC (the “Sponsor”).”
Tevogen Bio Holdings Inc. received a nasdaq compliance regained notice regarding other (rules 5250(f)).
“May 5, 2023, the Company received notification from Nasdaq that the fee delinquency was cured and the Company is now in compliance with Nasdaq’s continued listing standards. The Company’ securities will continue to trade on The Nasdaq Stock Market, and Nasdaq considers the matter closed.”
Tevogen Bio Holdings Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“April 4, 2023, Semper Paratus Acquisition Corporation (the “Company”) received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securi”
Tevogen Bio Holdings Inc. received a nasdaq delisting notice notice regarding other (rules 5250(f)).
“ule or Standard; Transfer of Listing On March 23, 2023, Semper Paratus Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications division of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has not paid certain fees required by Nasdaq Listing Rule 5250(f) and that the Company will be delisted unless it appeals such determination. As of the date of the Notice, the Company’s past due fee balance totaled $151,000. If the Company elects not to appeal, trading of its Class A ordinary shares will be suspended at the opening of business on April 3”
Tevogen Bio Holdings Inc.: Approved an amendment to extend the deadline for consummating an initial business combination from February 8, 2023 to December 15, 2023 (effective 2023-02-03).
“the shareholders of the Company approved an amendment (the “Charter Amendment”) to the Company’s Amended and Restated Memorandum and Articles of Association to extend the date by which the Company must consummate an initial business combination from February 8, 2023 to December 15, 2023. Under Cayman Islands law, the Charter Amendment took effect upon approval by the shareholders.”
Tevogen Bio Holdings Inc. shareholders approved Approval of Charter Amendment at the 2023-02-03 meeting.
“otes: For Against Abstain 35,386,187 4,266,453 0 The adjournment proposal was not presented to the shareholders because there were sufficient votes to approve the Charter Amendment.”
Jeff Rogers was appointed as Chief Financial Officer and Secretary at Tevogen Bio Holdings Inc..
“Effective as of April 13, 2022, the Board of Directors of the Company appointed Jeff Rogers to serve as the Company’s Chief Financial Officer and Secretary.”
Philippe J. Kurzweil resigned as Chief Financial Officer and Secretary at Tevogen Bio Holdings Inc..
“On April 13, 2022, Philippe J. Kurzweil voluntarily resigned, effective immediately, as the Chief Financial Officer and Secretary of Semper Paratus Acquisition Corporation (the “Company”).”
Parizad Olver Parchi was appointed as Director at Tevogen Bio Holdings Inc..
“Effective November 3, 2021, Brad Stewart and Parizad Olver Parchi were appointed to the board of directors of the Company (the “ Board ”).”
Brad Stewart was appointed as Director at Tevogen Bio Holdings Inc..
“Effective November 3, 2021, Brad Stewart and Parizad Olver Parchi were appointed to the board of directors of the Company (the “ Board ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.